thumbnail image
broken image
broken image
broken image
  • Home
  • About us 
    • Management
    • Living Innovation
    • Company presentation
  • Science 
    • Pipeline
    • xLink MAb platform
    • TROY-Ig TCE platform
    • Publications
  • Patient 
    • Cancer Immunotherapy
    • LVGN6051
    • LVGN7409
    • LVGN3616
    • Resources
  • News 
    • News
    • Company presentation
  • Partners 
    • Careers
    • Collaboration
    • Contact us
  • …  
    • Home
    • About us 
      • Management
      • Living Innovation
      • Company presentation
    • Science 
      • Pipeline
      • xLink MAb platform
      • TROY-Ig TCE platform
      • Publications
    • Patient 
      • Cancer Immunotherapy
      • LVGN6051
      • LVGN7409
      • LVGN3616
      • Resources
    • News 
      • News
      • Company presentation
    • Partners 
      • Careers
      • Collaboration
      • Contact us
broken image
broken image
broken image
  • Home
  • About us 
    • Management
    • Living Innovation
    • Company presentation
  • Science 
    • Pipeline
    • xLink MAb platform
    • TROY-Ig TCE platform
    • Publications
  • Patient 
    • Cancer Immunotherapy
    • LVGN6051
    • LVGN7409
    • LVGN3616
    • Resources
  • News 
    • News
    • Company presentation
  • Partners 
    • Careers
    • Collaboration
    • Contact us
  • …  
    • Home
    • About us 
      • Management
      • Living Innovation
      • Company presentation
    • Science 
      • Pipeline
      • xLink MAb platform
      • TROY-Ig TCE platform
      • Publications
    • Patient 
      • Cancer Immunotherapy
      • LVGN6051
      • LVGN7409
      • LVGN3616
      • Resources
    • News 
      • News
      • Company presentation
    • Partners 
      • Careers
      • Collaboration
      • Contact us
broken image
  • Publications

  • ASCO 2024 Poster for Abstract # 2575 " Efficacy, Safety, and PK/PD of LVGN6051, 4-1BB agonistic antibody, with pembrolizumab in a Phase Ib dose expansion in resistant NSCLC, Melanoma, and GI malignancy" (Download PDF)

     

    ASCO 2024 Poster for Abstract # 11554 "An open label, phase 1b/2 trial of LVGN6051 (4-1BB agonistic antibody) combined with anlotinib for refractory soft tissue sarcoma (STS)." (Download PDF)

     

    ASCO 2023 Poster for Abstract # 2525 "First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors" . Download PDF

     

    Liu, L., Y. Wu, K. Ye, M. Cai, G. Zhuang and J. Wang (2022). "Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking." Frontiers in Pharmacology 13. Download PDF


    Qi, X., F. Li, Y. Wu, C. Cheng, P. Han, J. Wang and X. Yang (2019). "Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity." Nature Communications 10(1): 2141. Download PDF

     

    Contact us
沪公网安备 31011502015346号
|
沪ICP备20018873号-2
    Home
    About us
    xLinkAb
    Contact us
Lyvgen Biopharma Website 礼进生物 英文官网
Lyvgen is a biotech company focused on developing novel therapies for cancer. Lyvgen’s xLinkAb™ functional platform creates agonist antibodies (Abs) with tumor-localized immunostimulatory activities by balancing multiple functions of candidate Abs.
https://user-assets.sxlcdn.com/images/676507/FiTA8WK-FQRyXrQDyd-HDkY3tpfI.png?imageMogr2/strip/auto-orient/thumbnail/1200x630>/format/png
Cookie的使用
我们使用cookies来确保流畅的浏览体验。若继续,我们认为你接受使用cookies。
了解更多